a hrefhttps:www.fiercepharma.compharmapfizer-taking-litfulo-regulators-vitiligo-challenge-incyte-abbvie hreflangenPfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbViea

In hopes of challenging Incytes topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmental vitiligo.